Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML is a PHASE3 clinical asset sponsored by Medical Research Council in Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms. SEO and diligence focus: filgrastim, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, tretinoin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.